Application of array-based genomic and epigenomic technologies to unraveling the heterogeneous nature of breast tumors: on the road to individualized treatment.
The recent application of genomic microarray technology to the molecular profiling of breast tumors has clearly demonstrated their heterogeneous nature. Targeted treatment strategies are having a clear impact on patient survival. It has also become apparent that accumulated mutations, genomic instability, epigenetic phenomena, genetic variability and environmental factors all contribute to the uniqueness of a patient's tumor. Novel genomic and epigenetic-based technologies have been or are being developed in order to greatly enhance the analysis of tumor samples including those samples previously thought unusable due to the fixation process, such as archival formalin-fixed paraffin-embedded (FFPE) samples. Patients and their tumors can now be studied with regard to genetic variation, genomic instability, gene expression, gene mutations, and methylation patterns. These areas of research are being made more accessible through genome-wide screening technologies and will, in the near future, rapidly expand our understanding of what contributes to the unique properties of each tumor and lead to the identification of genes that could be potential therapeutic targets for specific tumor subtypes. Application of these technologies to our understanding of breast cancer will undoubtedly have an impact on the individualization of treatment for breast cancer patients in the not to distant future.